368 related articles for article (PubMed ID: 33051339)
21. Myeloid-Derived Suppressor Cells in Sepsis.
Schrijver IT; Théroude C; Roger T
Front Immunol; 2019; 10():327. PubMed ID: 30873175
[TBL] [Abstract][Full Text] [Related]
22. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies.
Fantini MC; Guadagni I
Dig Liver Dis; 2021 May; 53(5):558-565. PubMed ID: 33541800
[TBL] [Abstract][Full Text] [Related]
23. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
24. Myeloid-derived suppressor cells-new and exciting players in lung cancer.
Yang Z; Guo J; Weng L; Tang W; Jin S; Ma W
J Hematol Oncol; 2020 Jan; 13(1):10. PubMed ID: 32005273
[TBL] [Abstract][Full Text] [Related]
25. IL-17A produced by peritoneal macrophages promote the accumulation and function of granulocytic myeloid-derived suppressor cells in the development of colitis-associated cancer.
Zhang Y; Wang J; Wang W; Tian J; Yin K; Tang X; Ma J; Xu H; Wang S
Tumour Biol; 2016 Dec; ():. PubMed ID: 27909978
[TBL] [Abstract][Full Text] [Related]
26. Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy.
Baniyash M
Cancer Immunol Immunother; 2016 Jul; 65(7):857-67. PubMed ID: 27225641
[TBL] [Abstract][Full Text] [Related]
27. Myeloid-Derived Suppressor Cells and Radiotherapy.
Jiménez-Cortegana C; Galassi C; Klapp V; Gabrilovich DI; Galluzzi L
Cancer Immunol Res; 2022 May; 10(5):545-557. PubMed ID: 35426936
[TBL] [Abstract][Full Text] [Related]
28. Myeloid-Derived Suppressor Cells in Solid Tumors.
Ma T; Renz BW; Ilmer M; Koch D; Yang Y; Werner J; Bazhin AV
Cells; 2022 Jan; 11(2):. PubMed ID: 35053426
[TBL] [Abstract][Full Text] [Related]
29. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
30. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.
Mortezaee K
Life Sci; 2021 Jul; 277():119627. PubMed ID: 34004256
[TBL] [Abstract][Full Text] [Related]
31. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression.
Yin K; Xia X; Rui K; Wang T; Wang S
Front Oncol; 2020; 10():610104. PubMed ID: 33384962
[TBL] [Abstract][Full Text] [Related]
32. Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more.
Shibata M; Nanno K; Yoshimori D; Nakajima T; Takada M; Yazawa T; Mimura K; Inoue N; Watanabe T; Tachibana K; Muto S; Momma T; Suzuki Y; Kono K; Endo S; Takenoshita S
Oncotarget; 2022 Nov; 13():1273-1285. PubMed ID: 36395389
[TBL] [Abstract][Full Text] [Related]
33. Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis.
He Y; Hung SW; Liang B; Zhang R; Gao Y; Chu CY; Zhang T; Xu H; Chung JPW; Wang CC
Front Immunol; 2021; 12():641206. PubMed ID: 34367125
[TBL] [Abstract][Full Text] [Related]
34. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
Netherby CS; Abrams SI
Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
[TBL] [Abstract][Full Text] [Related]
36. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
Qu P; Wang LZ; Lin PC
Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
[TBL] [Abstract][Full Text] [Related]
37. Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.
Zhang J; Hodges A; Chen SH; Pan PY
Cell Immunol; 2021 Apr; 362():104300. PubMed ID: 33582607
[TBL] [Abstract][Full Text] [Related]
38. CD30L/CD30 signaling regulates the formation of the tumor immune microenvironment and inhibits intestinal tumor development of colitis-associated colon cancer in mice.
Wang X; Gao Y; Zhang X; Wang X; Wang B; Meng X; Yoshikai Y; Wang Y; Sun X
Int Immunopharmacol; 2020 Jul; 84():106531. PubMed ID: 32353687
[TBL] [Abstract][Full Text] [Related]
39. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
40. Loss of acid ceramidase in myeloid cells suppresses intestinal neutrophil recruitment.
Espaillat MP; Snider AJ; Qiu Z; Channer B; Coant N; Schuchman EH; Kew RR; Sheridan BS; Hannun YA; Obeid LM
FASEB J; 2018 May; 32(5):2339-2353. PubMed ID: 29259036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
